The critical limb ischemia treatment market is majorly driven by the rising burden of peripheral artery disease and diabetes. CLI occurs due to severe blockage of arteries which reduces blood flow to arms and legs. Advanced treatment options like drug-coated balloons and stents, minimally invasive surgeries and hybrid procedures are improving clinical outcomes for patients.
The global critical limb ischemia treatment market is estimated to be valued at US$ 9.11 Bn in 2024 and is expected to exhibit a CAGR of 8.5% over the forecast period 2024 to 2031.
Key Takeaways
Companies operating in the Critical Limb Ischemia Treatment Market Share are Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Cook Medical Inc., Cardiovascular Systems, Inc., Philips Healthcare, B. Braun Melsungen AG, Terumo Corporation, Biotronik SE & Co. KG, Cordis Corporation, Smith & Nephew plc, Stryker Corporation, AngioDynamics, Inc., GE Healthcare, Sanofi S.A., AstraZeneca plc, and Bristol-Myers Squibb Company. The growing prevalence of diabetes is expected to drive the demand for critical limb ischemia treatments. Advancements indrug-coated balloon technologies, minimally invasive surgeries and hybrid procedures have expanded treatment options and improved clinical outcomes for patients.
Market Trends
Increasing adoption of drug-coated balloon catheters: Drug-coated balloons offer localized drug delivery with reduced systemic exposure. They are rapidly gaining acceptance as first line treatment for CLI. Growing research on drug combinations is further expanding their application scope.
Rising popularity of minimally invasive and hybrid procedures: Advanced endovascular tools allow performing complex revascularization via small incisions. Hybrid operations combining open and endovascular techniques tailored to individual patient anatomies are delivering superior results compared to conventional therapies. This is bolstering the critical limb ischemia treatment market growth.
Market Opportunities
Development of novel bioactive coatings: Emerging biomimetic, pro-healing coatings can enhance treatment efficacy. Their ability to stimulate tissue regeneration post-revascularization offers an opportunity to expand the treatment algorithm beyond standard revascularization.
Improving accessibility in developing regions: Partnerships between device firms and healthcare providers, financing options and optimal care models can play a key role in addressing CLI in underserved communities and drive critical limb ischemia treatment market expansion.
Impact of COVID-19 on Critical Limb Ischemia Treatment Market:
The outbreak of COVID-19 has impacted the Global Critical Limb Ischemia Treatment Market Growth negatively. Currently there is less demand from healthcare facilities due to concerns over COVID-19 transmission and restrictions on non-emergency medical procedures. Though critical limb ischemia is considered an emergency condition, fewer patients are willing to visit hospitals for treatment during the pandemic. Resources were also reallocated to COVID-19 management which affected critical limb ischemia diagnostics and treatments. Post COVID, demand is projected to surge again as healthcare resources become available and patient willingness increases. However, there may be a backlog that providers need to clear. Telehealth can play a greater role to virtually consult and triage patients to prioritize the critically ill. The industry may focus more on at-home diagnostics and therapies to offer safer options. Strategically increasing production capacities of devices that enable remote care models could boost market recovery.
In terms of geographical regions where value is concentrated, North America accounted for the major market share of critical limb ischemia treatment. High healthcare expenditure, advanced medical infrastructure, favorable reimbursement policies, and presence of key market players in the US and Canada drive the regional market growth. However, Asia Pacific is projected as the fastest growing region due to rising healthcare awareness, improving access and facilities, increasing lifestyle diseases and expanding private insurance coverage in major countries. With growing investments to strengthen healthcare systems, demand isforecast to increase at a higher rate in Asia Pacific compared to other regions in the coming years.
Get more insights on Critical Limb Ischemia Treatment Market
About Author
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
Comments
0 comment